Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years.
Danaher: Near 5-Year Low Is A Great Entry Point
Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years.
Here's Why You Should Avoid Betting on Danaher Stock Right Now
Persistent softness in the Life Sciences segment weighs on DHR's performance. An increase in operating expenses is an added concern.
Danaher Corporation (DHR) TD Cowen 45th Annual Health Care Conference Transcript
Danaher Corporation (NYSE:DHR ) TD Cowen 45th Annual Health Care Conference Call March 5, 2025 10:30 AM ET Company Participants Rainer Blair – President and Chief Executive Officer Conference Call Participants Dan Brennan – TD Cowen Dan Brennan Welcome to day-three of the TD Cowen Global Healthcare Conference. I'm Dan Brennan, I follow tools and diagnostics.
Danaher Rewards Shareholders With 18.5% Dividend Increase
DHR's measures to consistently reward shareholders through dividends and share buybacks hold promise.
Danaher: Self-Inflicted Pessimism?
Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company's strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher's bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment.
Danaher Analysts Cut Their Forecasts After Downbeat Earnings
Danaher Corporation DHR reported weaker-than-expected fourth-quarter earnings on Wednesday.
Danaher Q4 Earnings Miss Estimates, Life Sciences Sales Rise Y/Y
DHR's fourth-quarter sales increase 2.1% year over year, benefiting from the solid performance of its Life Sciences and Biotechnology segments.
Danaher (DHR) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
Danaher (DHR) Lags Q4 Earnings Estimates
Danaher (DHR) came out with quarterly earnings of $2.14 per share, missing the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.09 per share a year ago.
Danaher misses quarterly profit estimates on weak biotech demand
Danaher on Wednesday missed Wall Street estimates for fourth-quarter profit due to soft demand for tools and services used in drug development by its biotech and pharmaceutical clients.
